Recent advances in stem cell biology have enabled the production of human induced pluripotent stem cells (hIPSCs) from different donors to become more routine ([@r1], [@r2]). hIPSCs can be generated from healthy individuals or from patients harboring mutations of clinical interest, facilitating studies on phenotypic--genotypic associations ([@r3], [@r4]). Inflammatory bowel disease (IBD) can develop in infants due to, among other causes, loss-of-function mutations in *IL10*, *IL10RA*, and *IL10RB* ([@r5], [@r6]). In addition to IBD with severe perianal disease, patients with IL-10--signaling defects develop chronic folliculitis and arthritis ([@r7]). The development of IBD involves complex interactions between host genetics that impact intestinal barrier function and intestinal immunity, the environment, and the intestinal microbiota ([@r8]).

IL10R2 encoded by the *IL10RB* gene is a component of the heterodimeric IL-10 receptor (IL10R) as well as a component of the receptor for IL-22 (IL22R). Due to the common IL10R2 receptor chain that can pair with several R1 subunits, patients with loss-of-function mutations in *IL10RB* are nonresponsive to the cytokines IL-10, IL-22, IL-26, IL-28A, IL-28B, and IL-29 ([@r5]). IL10R2 is expressed constitutively across many cell types in the body, whereas IL22R1 is expressed mainly on nonhematopoietic cells lining barrier sites, including the intestine ([@r9][@r10]--[@r11]). A key role for IL-22 is maintenance of the gastrointestinal barrier. Mice deficient in IL-22 or the IL-22 receptor Il22ra1 can be susceptible to severe disseminated bacterial infection after chemically induced colitis or *Citrobacter rodentium* challenge ([@r12], [@r13]).

Intestinal organoids are beginning to provide a reductionist system to dissect the cell-intrinsic role of intestinal epithelial cells (IECs) in host defense. Murine intestinal organoids exposed to IL-22 displayed evidence of an inflammatory response, enhanced antimicrobial activity, and wound healing ([@r12]). Here, we explore the role of IL-22 in priming IEC responses to the enteric pathogen *Salmonella enterica* serovar Typhimurium, using hIPSC-derived intestinal organoids (iHOs), including those generated from a patient with infantile IBD due to an *IL10RB* defect, as a model system. Our results provide insights into an IL-22--driven bacterial defense mechanism involving enhanced phagolysosomal fusion.

Results {#s1}
=======

iHOs Derived from a Patient with Infantile IBD Lack Expression of *IL10RB*. {#s2}
---------------------------------------------------------------------------

To explore whether iHOs provide a suitable system to study the IL-22 pathway, the expression patterns of mRNAs encoding IL22R1 and IL10R2, the receptor subunits for IL-22, were examined in iHOs derived from hIPSCs using our established protocol ([Fig. 1](#fig01){ref-type="fig"}) ([@r14]). iHOs were differentiated from the independently derived hIPSC lines Yemz1, Lise1, and Kolf2 as well as from hIPSCs derived from an individual with infantile IBD who harbored a homozygous splice site mutation at the boundary between intron and exon 3 in the *IL10RB* gene (hereafter "IL10RB^Pat^") ([@r7]). Six weeks after the generation of iHOs from each hIPSC line, the resulting iHOs were phenotyped for expression of markers of mature intestinal epithelium ([Fig. 1](#fig01){ref-type="fig"} and [*SI Appendix*, Fig. S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). mRNA was detected for *IL22RA* and *IL10RB* in iHOs from all lines, but significantly lower mRNA levels of *IL10RB* were detected in the IL10RB^Pat^ iHOs than in healthy control iHO lines ([Fig. 1*A*](#fig01){ref-type="fig"}). However, in contrast to mapped RNA-sequencing (RNA-seq) reads from Kolf2 iHOs, no reads mapped to exon 3 in the corresponding IL10RB^Pat^ iHO samples ([*SI Appendix*, Fig. S2*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). To generate a complemented isogenic control line for IL10RB^Pat^ (hereafter "IL10RB^Comp^"), TALEN-based engineering was used to introduce a functional *IL10RB* gene into the adeno-associated virus site 1 (*AAVS1* site) in the IL10RB^Pat^ genome ([@r15], [@r16]). After transfection and 7-d puromycin selection, RT-qPCR was performed on surviving colonies with *IL10RB*-specific primers to detect mRNA expression. One clone was selected for differentiation; the quantity and morphology of hIPSC colonies for this clone were indistinguishable from control hIPSCs. RNA was prepared from differentiated IL10RB^Pat^ and IL10RB^Comp^ iHOs, which displayed phenotypes similar to healthy control iHOs in culture ([*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)), and from their hIPSC progenitors, and levels of *IL10RB* mRNA were assayed by RT-qPCR ([Fig. 1*B*](#fig01){ref-type="fig"}). *IL10RB* gene expression was significantly higher in IL10RB^Comp^ iHOs than in IL10RB^Pat^ iHOs. At the protein level, IL22R1 and IL10R2 expression was observed on the basal surface of Kolf2 iHOs but not IL10RB^Pat^ iHOs using immunostaining ([Fig. 1*C*](#fig01){ref-type="fig"}). The IL22R1 protein was clearly visible dispersed across the basal surface of the iHO epithelia. In contrast, the IL10R2 protein was more obvious as clusters associated with individual cells, often colocalizing with markers for enteroendocrine cells, a feature observed in both iHOs ([*SI Appendix*, Fig. S2*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)) and primary intestinal tissue ([*SI Appendix*, Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). As expression of receptors was basal, in subsequent assays IL-22 was delivered to the basal surface of iHOs. Although expression of *IL10RB* was consistent in healthy control hIPSC lines ([Fig. 1*A*](#fig01){ref-type="fig"}), *IL10RB* expression was routinely higher in IL10RB^Comp^ hIPSCs, probably due to the use of a different promoter ([Fig. 1*B*](#fig01){ref-type="fig"}). However, expression of IL10R2 protein was detected in IL10R2^Comp^ iHOs at comparable levels to expression in Kolf2 iHOs ([Fig. 1*C*](#fig01){ref-type="fig"}). In control human ileal and colonic tissue similar patterns of marker staining were observed to iHOs ([*SI Appendix*, Fig. S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). To confirm the lack of surface expression of IL10R2 in IL10RB^Pat^ iHOs, flow cytometry was performed. In Kolf2 iHOs 6% of IECs were positive for IL10R2 expression, confirming the diffuse expression observed via immunostaining, whereas IL10RB^Pat^ iHOs were entirely negative ([*SI Appendix*, Fig. S2*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)).

![Analysis of expression of IL-22R subunits IL22R1 and IL10R2 demonstrated that iHOs generated from healthy control hIPSCs express the receptors for IL-22, IL22R1, and IL10R2, in contrast to iHOs generated from a patient with infantile IBD, which lack the IL10R2 subunit. To generate IL10RB^Comp^, an isogenic control line for patient iPSCs (IL10RB^Pat^), TALEN-mediated gene integration was used to integrate a copy of the *IL10RB* gene into the AAVS1 site in IL10RB^Pat^ iPSCs. (*A*) mRNA levels determined by RT-qPCR for *IL22RA* and *IL10RB* in three healthy control iHO lines (Yemz1, Lise1, and Kolf2), IL10RB^Pat^ iHOs, and control duodenal tissue. IL10RB is significantly up-regulated in control iHOs in comparison with IL10RB^Pat^ (*P* = 0.0005, *P* \< 0.0001, and *P* \< 0.0001, respectively; Student's *t* tests). (*B*) RT-qPCR analysis shows significant up-regulation of *IL10RB* expression in IL10RB^Comp^ iHOs in comparison with IL10RB^Pat^ iHOs (*P* \< 0.0001; unpaired, two-tailed Student's *t* test). RT-qPCR was performed with TaqMan gene-expression assays and analyzed via the comparative cycle threshold (C~T~) method with *GAPDH* as an endogenous control. Data are presented from four technical replicates, with assays repeated at least three times from independent iHO batches. \*\**P* \< 0.001; \*\*\**P* \< 0.0001. (*C*) Z-stacked immunostaining for IL-22 receptors IL10R2 or IL22R1 (green) and DAPI (blue) on healthy control Kolf2, IL10RB^Comp^, and IL10RB^Pat^ iHOs showing localization of IL22R1 and IL10R2 on the basal IEC surface, with IL10R2 not detected in IL10RB^Pat^ iHOs. (Original magnification: 20×.)](pnas.1811866115fig01){#fig01}

IL10R2 Is Necessary for iHO Responses to IL-22. {#s3}
-----------------------------------------------

To probe for transcriptional changes in IL-22--prestimulated iHOs, a global transcriptomic analysis was performed in Kolf2 iHOs that were left untreated or were treated with IL-22 for 18 h ([*SI Appendix*, Fig. S5 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). Principal component analysis ([*SI Appendix*, Fig. S5*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)) showed that iHOs treated with IL-22 and untreated iHOs formed distinct groups. A heatmap for the 30 most highly up-regulated IL-22--responsive genes ([*SI Appendix*, Fig. S5*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental) and [Datasets S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental) and [S2](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)) included the antimicrobial proteins REGIIIα and REGIβ and the mucin-encoding gene *MUC1*, which are potentially expressed by Paneth and goblet cells, respectively. Several IFN-regulated genes associated with antiviral and antimycobacterial defenses, including *IFITM1*, *IFITM2*, and *IFITM3*, were relatively up-regulated ([@r17]). Components involved in the maturation and processing of the epithelial oxidase complex DUOX2, *DUOXA2*, and *DUOXA1* were also up-regulated ([@r18]), along with *DMBT1*, which can restrict *Salmonella* entry into cultured IECs ([@r19]). When treated with IL-22 for 18 h, Yemz1, Lise1, and Kolf2 iHOs significantly up-regulated *DUOX2* and *LCN2* mRNA ([Fig. 2*A*](#fig02){ref-type="fig"}), previously demonstrated to be regulated by IL-22 in other model systems ([@r12], [@r20]). Levels of *DUOX2* and *LCN2* mRNA did not change significantly in IL10RB^Pat^ iHOs after IL-22 treatment; however, the IL-22 response was restored in IL10RB^Comp^ iHOs ([Fig. 2*A*](#fig02){ref-type="fig"}). At earlier time points of 3 and 6 h we did not observe up-regulation of *DUOX2* and *LCN2* ([*SI Appendix*, Fig. S5*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). STAT3 activation was detected by Western blotting in whole-cell lysates from healthy controls (Kolf2 and Yemz1 iHOs) and IL10RB^Comp^ iHOs but not the IL10RB^Pat^ iHOs after 30-min treatment with IL-22 ([Fig. 2*B*](#fig02){ref-type="fig"}). To visualize changes in the barrier phenotype of iHOs treated with IL-22, we performed immunostaining with antibodies for Mucin 4 after IL-22 treatment ([Fig. 2*C*](#fig02){ref-type="fig"}), showing enhanced Mucin 4 production. Mucin 4 production was also enhanced in IL10RB^Comp^ iHOs but not in IL10RB^Pat^ iHOs ([Fig. 2*D*](#fig02){ref-type="fig"}). We have shown here that, after IL-22 treatment, iHOs up-regulated various antimicrobials and components of the intestinal barrier defense. Hence, we performed RNA-seq and subsequent gene-expression analyses for mRNA in Kolf2 iHOs treated with IL-22 alone or with *S. enterica* Typhimurium SL1344 added to the medium for 3 h. *S*. *enterica* Typhimurium exacerbated the expression of numerous genes in iHOs ([*SI Appendix*, Fig. S5*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental) and [Datasets S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental) and [S4](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)), which was confirmed using RT-qPCR for *LCN2*, *DUOX2*, and *CXCL2* ([*SI Appendix*, Fig. S5*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). Therefore, we hypothesized that during infection IL-22--pretreated iHOs might be less susceptible to invasion by *S. enterica* Typhimurium SL1344 due to the induction of barrier and host defense mechanisms by IL-22 treatment.

![Expression of *IL10RB* was required for iHO responses to IL-22. iHOs were treated with 100 ng/mL recombinant human IL-22 (rhIL-22) added to the iHO medium. (*A*) In iHO lines with a functional copy of *IL10RB*, transcripts for IL-22--regulated genes lipocalin 2 (*LCN2*) and dual oxidase 2 (*DUOX2*) are significantly up-regulated after the addition of 100 ng/mL rhIL-22 for 18 h, in comparison with unstimulated iHOs (\*\**P* \< 0.001; \*\*\**P* \< 0.0001; unpaired, two-tailed, Student's *t* tests; n.s., not significant). Data are presented from four technical replicates; assays were repeated with at least three biological replicates. RT-qPCR was performed with TaqMan gene-expression assays and analyzed via the comparative C~T~ method with *GAPDH* as an endogenous control. (*B*) Phospho-STAT3 level was detected by Western blot after stimulation of healthy control (Yemz1 and Kolf2), IL10RB^Pat^, and IL10RB^Comp^ iHOs for 30 min with rhIL-22 and preparation of whole-cell extracts. To verify equal protein loading, the blot was stripped and reprobed with STAT3 antibody. Lysate from HeLa cells stimulated with IFNλ were used as a positive control. (*C*) Kolf2 iHOs challenged with IL-22 for 18 h or left untreated were examined for Mucin 4 (MUC4; green) and DAPI (blue) by immunofluorescence. (*D*) Z-stacked immunostaining for Mucin 4 in IL10RB^Pat^ and IL10RB^Comp^ iHOs challenged with IL-22 for 18 h or were left untreated. (Original magnification: 20×; L = iHO lumen.)](pnas.1811866115fig02){#fig02}

IL-22 Induces a Protective Phenotype Against *S. enterica* Serovar Typhimurium Infection in iHOs. {#s4}
-------------------------------------------------------------------------------------------------

To establish whether IL-22 had an effect on the early interaction of *S. enterica* Typhimurium with iHOs, we pretreated iHOs with IL-22 for 18 h and then performed microinjections with *S. enterica* Typhimurium SL1344 ([Fig. 3](#fig03){ref-type="fig"}). Interestingly, modified gentamicin protection assays measuring bacterial intracellular survival demonstrated that in Kolf2 and IL10RB^Comp^ iHOs significantly less *S. enterica* Typhimurium was recovered from IL-22--pretreated iHOs than from untreated iHOs, in contrast to IL10RB^Pat^ iHOs, in which no significant difference was observed between pretreated and untreated iHOs ([Fig. 3*A*](#fig03){ref-type="fig"}). We then performed similar assays in Kolf2, IL10RB^Comp^, and IL10RB^Pat^ iHOs using a fluorescently tagged *S. enterica* Typhimurium SL1344 (TIMER^bac^-*Salmonella*) ([Fig. 3*B*](#fig03){ref-type="fig"}), which can yield bright fluorescence in the green/orange channel, depending on replication state ([@r21]). The percentage differences in *Salmonella* counts between untreated and IL-22--pretreated iHOs in the IL10RB^Pat^ samples were significantly lower than the corresponding differences between untreated and IL-22--pretreated iHOs in the Kolf2 and IL10RB^Comp^ iHOs. These protection assays were designed to measure differences in levels of intracellular bacteria. In addition, we performed luminal killing assays using *S. enterica* Typhimurium SL1344 and an *S*. Typhimurium SL1344 *invA* mutant, which we have previously shown to be ∼30 times less invasive in the iHO system ([Fig. 3*C*](#fig03){ref-type="fig"}) ([@r14]). In these assays bacteria were harvested directly from the iHO luminal cavity. There was no significant difference in the counts recovered from untreated or IL-22--pretreated iHOs, suggesting that luminal killing did not explain the phenotypic differences observed in the invasion assays. We also measured initial invasion by performing protection assays with intracellular bacteria harvested after 30 min ([Fig. 3*E*](#fig03){ref-type="fig"}). Here, we saw a significant reduction in intracellular *S. enterica* Typhimurium counts in Kolf2 iHOs prestimulated with IL-22, suggesting that the initial invasion was inhibited by IL-22. However, assays were also performed to assess longer-term intracellular survival by incubating infected iHOs for a further 90 min post infection ([Fig. 3*E*](#fig03){ref-type="fig"}). Here, a greater difference was observed in bacterial counts recovered from IL-22--pretreated iHOs compared with untreated iHOs.

![Pretreatment with rhIL-22 of iHOs that express both IL22R1 and IL10R2 restricts *S. enterica* Typhimurium SL1344 invasion into IECs. For protection assays iHOs were treated with 100 ng/mL IL-22 18 h before infection or were left untreated. After injection of *S. enterica* Typhimurium SL1344 into the luminal cavity, iHOs were incubated for 90 min unless otherwise stated. Bacteria were recovered either from the luminal cavity or from IECs. The data presented show the mean from three technical replicates from the combined total of 25 iHOs per replicate, ± SEM, unless otherwise stated. For significance testing unpaired, two-tailed, Mann--Whitney *U* tests were used for all assays. \**P* \< 0.05; \*\**P* \< 0.001; \*\*\**P* \< 0.0001; n.s., not significant. (*A*) Gentamicin protection assays in iHOs show that pretreatment with IL-22 results in significantly less invasion after microinjection of *S. enterica* Typhimurium SL1344 in healthy control lines with functional IL10R2 (Kolf2: *P* = 0.0012; IL10R2^Comp^: *P* \< 0.0001), but this phenotype is not observed in IL10RB^Pat^ iHOs (*P* = 0.2). (*B*) Percentage difference in TIMER^bac^ *Salmonella*-infected cells assayed by flow cytometry recovered from untreated or IL-22--treated iHOs (40 iHOs per condition), with gating on live cells. There were significant differences between Kolf2 samples (*P* = 0.0214) or IL10RB^Comp^ samples and IL10RB^Pat^ samples (*P* = 0.0002; Kruskal--Wallis test with Dunn's multiple comparison test). (*C*) Log numbers of cfu/mL recovered from lumens of iHOs after microinjection of untreated or IL-22--pretreated Kolf2 iHOs with SL1344 or an invasion-deficient strain, *S. enterica* Typhimurium SL1344 *inv*A. There was no significant difference in numbers recovered. (*D*) Protection against *S. enterica* Typhimurium infection after IL-22 pretreatment is observed in human primary duodenal organoids. Data presented show the mean from three biological replicates with 10 organoids injected per replicate, ± SEM (*P* \< 0.0001). (*E*) Modified gentamicin protection assays in Kolf2 iHOs show that pretreatment with IL-22 results in significantly less initial invasion (30-min incubation) after microinjection of *S. enterica* Typhimurium SL1344 (*P* \< 0.0001) and also significantly less intracellular survival, when infected iHO IECs were incubated for an additional 90 min after gentamicin treatment and before IEC lysis (*P* \< 0.0001).](pnas.1811866115fig03){#fig03}

IL-22 Induces a Protective Phenotype in Primary Mouse and Human Organoids. {#s5}
--------------------------------------------------------------------------

To ensure that IL-22--mediated restriction was not an artifact of the iHO system, we repeated gentamicin protection assays in primary organoid systems ([Fig. 3*D*](#fig03){ref-type="fig"} and [*SI Appendix*, Fig. S6*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). In primary human duodenal organoids pretreated with IL-22 we recovered significantly fewer cfu/mL in protection assays ([Fig. 3*D*](#fig03){ref-type="fig"}) and confirmed the up-regulation of IL-22--responsive genes assayed by RT-qPCR ([*SI Appendix*, Fig. S6 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)).To confirm that IL-22--mediated protection was driven by signaling via IL22R1, murine intestinal organoids (iMOs) were generated from mucosal tissue harvested from wild-type and *Il22ra1*^−/−^ mice, and protection assays were performed ([*SI Appendix*, Fig. S6*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). In iMOs derived from *Il22ra1*^−/−^ mice there was no significant difference in the bacterial numbers recovered upon IL-22 treatment.

The Protective Phenotype Induced by IL-22 Pretreatment of iHOs Is Driven by Enhanced Phagolysosomal Fusion. {#s6}
-----------------------------------------------------------------------------------------------------------

Our protection assays demonstrated that intracellular survival in IL-22--pretreated iHOs was significantly reduced, suggesting differences in the intracellular environment after induction of IL-22 signaling ([Fig. 3](#fig03){ref-type="fig"}). Therefore, transmission electron microscopy (TEM) was used to image intracellular bacterial populations at high resolution ([Fig. 4](#fig04){ref-type="fig"} and [*SI Appendix*, Fig. S7 *A* and *B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). Interestingly, a distinct difference in bacterial populations was observed within IL-22--treated compared with untreated iHOs. In IL-22--pretreated iHOs, bacteria were visibly more degraded based on the scoring system presented in [*SI Appendix*, Fig. S7*B*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental). Histopathological scores from 100-μM sections of 1 mm of iHO mucosa demonstrated that there were more degraded bacteria in Kolf2 iHOs pretreated with IL-22 than in untreated iHOs (49 in pretreated iHOs vs. 11 in untreated iHOs). Moreover, more phagolysosomes were observed in IL-22--pretreated iHOs. To test this observation quantitatively, we used blinded scoring and collected counts for bacterial localization according to the feature scoring system presented in [*SI Appendix*, Fig. S7*A*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental). In IL-22--responsive iHOs, the proportion of phagolysosomes to total *Salmonella*-containing vacuoles (SCVs) was significantly higher in iHOs pretreated with IL-22 before infection than in untreated iHOs ([*SI Appendix*, Table S1](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). In IL10RB^Pat^ iHOs this phenotype was lost. IL-22 can restrict the growth of *Mycobacterium tuberculosis* intracellularly in macrophages by enhancing phagolysosomal fusion ([@r22]) and could be blocked by treatment with the phagolysosomal fusion inhibitor W7. W7 is a specific inhibitor of Ca^2+^/calmodulin interactions with binding partners, which have been shown to be part of a signaling pathway necessary for converting phagosomes into phagolysosomes ([@r23]). We added W7 for 6 h to iHOs pretreated with IL-22 for 18 h before infection with *S. enterica* Typhimurium SL1344. This revealed that, in the presence of W7, intracellular bacterial counts recovered were similar to those recovered from untreated iHOs ([Fig. 5*A*](#fig05){ref-type="fig"}). This phenotype was then replicated using concanamycin A, a vacuolar ATPase inhibitor that is also known to inhibit phagolysosomal fusion and acidification of phagosomes ([Fig. 5*A*](#fig05){ref-type="fig"}) ([@r24], [@r25]). To confirm that W7 and concanamycin A were not impacting bacterial invasion by restricting any other pathways, invasion assays with *S. enterica* Typhimurium in Kolf2 iHOs were repeated, and iHOs were treated with either W7 or concanamycin A ([*SI Appendix*, Fig. S7*C*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)) or were left untreated; no significant difference in recovered intracellular bacteria was observed. W7 and CCMA assays were repeated in IL10RB^Pat^ and IL10RB^Comp^ iHOs, demonstrating that in IL10RB^Comp^ blocking of phagolysosomal fusion with W7 also inhibited IL-22--mediated intracellular *S. enterica* Typhimurium restriction ([*SI Appendix*, Fig. S7*E*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). It is well established that the Rab family GTPase RAB7 marks late endosomes and late phagosomes ([@r26]). Therefore, we performed RT-qPCR and immunostaining of infected iHOs with RAB7-specific primers or antibodies. In Kolf2 iHOs a significant difference in fold change of *RAB7A* was observed between iHOs pretreated with IL-22 and those left untreated before infection ([Fig. 5*B*](#fig05){ref-type="fig"}). We also observed strong RAB7 staining in *S. enterica* Typhimurium-infected iHOs pretreated with IL-22, with visible colocalization between CSA-1, which stains *Salmonella*, and RAB7 ([Fig. 5*D*](#fig05){ref-type="fig"}). This phenotype was lost in IL10RB^Pat^ iHOs and was restored in IL10RB^Comp^ iHOs ([*SI Appendix*, Fig. S7*D*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). In addition, less RAB7 expression via immunostaining was observed in iHOs in which W7 was added before microinjection of *S. enterica* Typhimurium SL1344 ([Fig. 5*D*](#fig05){ref-type="fig"}, *Bottom*).

![IL-22 protection was mediated through enhanced lysosomal fusion with SCVs in IL-22--treated iHOs. TEM images of *S. enterica* Typhimurium SL1344 internalized into IECs 90 min after injection into the lumen of Kolf2 iHOs pretreated for 18 h with 100 ng/mL IL-22 (*Lower*) or left untreated (*Upper*), showing healthy bacteria in untreated organoids and degraded bacteria, often associated with lysosomes, in IL-22--pretreated iHOs. Representative images for each treatment condition were selected from 30 iHOs injected and processed per condition. Numbers indicate characterizations of bacterial cell damage/stress used for scoring: widening of periplasmic space (1); membrane damage and ragged appearance (2); decrease in cytosol density (3); direct contact with lysosomes (4); and presence of volutin granules (5).](pnas.1811866115fig04){#fig04}

![IL-22--induced calgranulin B enhanced iHO colonization resistance to *S. enterica* Typhimurium infection. (*A*) Direct blocking of phagolysosomal fusion with phagolysosomal inhibitors restricts IL-22--mediated protection in iHOs. Kolf2 iHOs were pretreated with 100 ng/mL IL-22 for 18 h and then were treated with the phagolysosomal inhibitors W7 at 50 μM for 6 h or concanamycin A (CCMA) at 100 nM for 4 h or were left untreated, after which gentamicin protection assays were performed. There was no significant difference in intracellular recovered bacteria from W7- or concanamycin A-treated iHOs and untreated iHOs (W7, *P* = 0.7015; CCMA *P* = 0.0631, IL-22, \*\*\**P* \< 0.0001; unpaired, two-tailed Mann--Whitney *U* tests). Data presented show the mean from four biological replicates with three technical replicates per assay, ± SEM. (*B* and *C*) RT-qPCR was performed with a TaqMan gene-expression assay specific for *RAB7A* (*B*) or *S100A9* (*C*) and was analyzed via the comparative C~T~ method with *GAPDH* as an endogenous control. Data presented show the mean fold change between untreated samples and infected samples from three biological replicates, ± SEM. There was a significant difference in *RAB7A* and *S100A9* expression in iHOs pretreated with IL-22 in comparison with iHOs left untreated before infection (*RAB7A*: *P* = 0.0001; *S100A9*: *P* \< 0.0001; unpaired, two-tailed Student's *t* tests). (*D*) Kolf2 iHOs challenged with IL-22 for 18 h or left untreated were microinjected with *S. enterica* Typhimurium SL1344 and examined for RAB7 (red), CSA-1 (green), and DAPI (blue) by immunofluorescence with colocalization between RAB7 and CSA-1 (yellow) visible in IL-22--pretreated samples. (Original magnification: 63×.) (*E*) Expression of S100A9 (green) by IL-22/*S. enterica* Typhimurium-treated Kolf2 and S100A9^−/−^ iHOs was examined using immunofluorescence. (*F*) Protection assays in S100A9^−/−^ iHOs show that pretreatment with IL-22 results in no significant difference in recovered intracellular bacterial after microinjection of *S. enterica* Typhimurium SL1344, in contrast to Kolf2 iHOs. (*G*) S100A9^−/−^ or Kolf2 iHOs treated with IL-22 for 18 h and then microinjected with *S. enterica* Typhimurium SL1344 were examined for RAB7 (red), CSA-1 (green), and DAPI (blue) by immunofluorescence; RAB7 was not visible in S100A9^−/−^ samples. (Original magnification: 40×.) n.s., not significant; \*\*\**P* \< 0.0001.](pnas.1811866115fig05){#fig05}

Calgranulin B Enhances IL-22--Induced Phagolysosomal Fusion. {#s7}
------------------------------------------------------------

Observations by Dhiman et al. ([@r27]) suggested that increased expression of calgranulin A (S100A8) was essential for IL-22--dependent mycobacterial growth inhibition through enhancement of phagolysosomal fusion. No differential expression of *S100A8* was observed in our RNA-seq experiments; however, increased expression of calgranulin B (*S100A9*) was observed after exposure of iHOs to IL-22 and *S. enterica* Typhimurium ([Dataset S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)), and was confirmed via RT-qPCR ([Fig. 5*C*](#fig05){ref-type="fig"}) and immunostaining ([*SI Appendix*, Fig. S7*G*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). S100A9 is induced by IL-6 signaling in colonic cells via the interaction of activated STAT3 with the *S100A9* promoter ([@r28]). Therefore, we reasoned that the IL-22 pathway might be triggering similar induction of S100A9 through STAT3 activation and thus decided to assess the role of S100A9 in IL-22--mediated phagolysosomal fusion. To this end, a biallelic mutation in *S100A9* was generated in Kolf2 hIPSCs using CRISPR/Cas9 engineering. In iHOs derived from S100A9^−/−^ hIPSCs, which were morphologically similar to other iHO lines ([*SI Appendix*, Fig. S3](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)), no expression of S100A9 protein via immunostaining was detected after stimulation with IL-22 and *S. enterica* Typhimurium SL1344 ([Fig. 5*E*](#fig05){ref-type="fig"}). Gentamicin protection assays in S100A9^−/−^ iHOs demonstrated no significant difference in intracellular *S. enterica* Typhimurium recovered from IL-22--pretreated iHOs in comparison with untreated iHOs ([Fig. 5*F*](#fig05){ref-type="fig"}), suggesting that IL-22--induced S100A9 directly inhibits *S. enterica* Typhimurium colonization. To ensure that this phenotype was not due to lack of IL-22 response in S100A9^−/−^ iHOs, mRNA levels of the IL-22--regulated genes *LCN2* and *DUOX2* were assessed after IL-22 treatment, revealing significant increases in the expression of both genes ([*SI Appendix*, Fig. S7*F*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental)). We then performed immunostaining for RAB7 in Kolf2 or S100A9^−/−^ iHOs treated with IL-22 and infected with *S. enterica* Typhimurium ([Fig. 5*G*](#fig05){ref-type="fig"}), observing a lack of RAB7 in S100A9^−/−^ iHOs.

Discussion {#s8}
==========

We have shown that iHOs generated from healthy control hIPSCs expressed IL-22 receptors on their basal surface and were responsive to IL-22. Conversely, IL-22 response was lost in iHOs generated from a patient with a loss-of-function mutation in *IL10RB*. Pretreatment of responsive iHOs with IL-22 appeared to drive a "barrier phenotype" as IL-22--primed iHOs were less susceptible to colonization by *S. enterica* Typhimurium, and prolonged incubation enhanced differences in bacterial survival. Through detailed imaging studies we attributed the IL-22--dependent protective phenotype to increased intracellular fusion of SCVs with lysosomes. Since fusion with the lysosome ends in degradation, some pathogens that enter the cell through the endocytic or phagocytic pathway are adapted to avoid this fusion ([@r29]). *S. enterica* Typhimurium has been shown to be capable of avoiding phagolysosomal fusion by modulating networks of Rab proteins that are recruited to the phagosome ([@r30]). To our knowledge, there have been no published reports showing that IL-22 prompts increased lysosomal fusion as a mechanism for restricting *S. enterica* Typhimurium growth in IECs. IL-22 can restrict the growth of *M. tuberculosis* intracellularly in macrophages by enhancing phagosomal fusion ([@r22]), and calgranulin A (S100A8) is required for this process ([@r27]). In iHOs we found that calgranulin B (S100A9) was required for IL-22--mediated intracellular killing. Further studies will be required to establish the functional relevance of this pathway in an intact immune system and to establish the specific interactions among S100A9, RAB7, and the phagolysome. Although our data suggest that IECs may be less susceptible to *S. enterica* Typhimurium colonization when the IL-22 pathway is functional, in vivo *Salmonella* has been observed to cross the epithelial barrier via M cells and direct capture from the lumen by phagocytes ([@r31]). This might help explain why *Il22*^*−/−*^ mice are not more susceptible to *S. enterica* Typhimurium infection in vivo, although this lack of susceptibility could also be attributable to depletion of the protective microbiota by IL-22--mediated antimicrobials ([@r20]). Here, our data showed differences after preincubation with IL-22 that might be more relevant to later stages of infection. However, in several models *S. enterica* Typhimurium has been shown to take longer than expected to breach the intestinal epithelium ([@r32]), and IL-22 expression, along with genes induced by IL-22, are highly expressed during the initial phases of infection ([@r33], [@r34]), suggesting that this pathway may also have an impact on earlier interactions in vivo.

It would be tempting to speculate that the phenotype of infantile severe colitis in IL10R2-deficient patients may be at least partially attributable to reduced barrier function at the epithelial tissues. In addition to their well-characterized defective response to the antiinflammatory cytokine IL-10 in immune cells ([@r35]), patients with IL10RB defects might also exhibit reduced barrier function ([@r7]). However, the clinical presentation in patients with loss of function mutations in *IL-10*, *IL10RA*, and *IL10RB* is similarly severe, and *IL10RB* mutations have not been associated with enhanced enteric infection, suggesting that this pathway in the epithelium may be redundant in vivo. Further understanding of the epithelial defects in patients with IL-10 signaling defects is becoming increasingly important, given that hematopoietic transplantation is a curative therapeutic option in patients with IL-10/IL10R deficiency ([@r7], [@r36]), and it will be important to investigate whether there are differences in the posttransplant intestinal infection susceptibility between patients with IL-10 and IL10RA defects on the one side and patients with IL10RB defects on the other.

Materials and Methods {#s9}
=====================

Generation and Culture of hIPSCs and Directed Differentiation to iHOs. {#s10}
----------------------------------------------------------------------

The healthy control hIPSC lines Yemz1, Lise1, and Kolf2, were acquired through the Human Induced Pluripotent Stem Cells Initiative Consortium (HipSci; [www.hipsci.org](http://www.hipsci.org/)), through which they were also characterized ([@r37]). Consent was obtained for the use of cell lines for the HIPSCI project from healthy volunteers. A favorable ethical opinion was granted by the National Research Ethics Service (NRES) Research Ethics Committee Yorkshire and The Humber -- Leeds West, reference number 15/YH/0391. IL10RB^Pat^ hIPSCs were generated at the Wellcome Trust Sanger Institute (WTSI) as part of the Oxford IBD cohort study/COLORS in IBD (Colitis of Early Onset---Rare Diseases Within IBD Disease Phenotypes) project with appropriate ethical approvals \[REC: 09/H1204/30; North Staffs Local Research Ethics Committee/NRES Committee West Midlands -- The Black Country (IBD in Oxford)\]. hIPSC lines were differentiated into endoderm, hindgut, and then iHOs using a previously published protocol ([@r14], [@r38]). For production of primary organoids, mucosal tissue was harvested and seeded according to protocols described by Sato and coworkers ([@r39]) and Fordham et al. ([@r40]). Control human intestinal samples were collected from the ascending colon and ileum of children under 16 y of age undergoing routine diagnostic endoscopy, following ethical approval (REC-12/EE/0482; NRES Committee East of England--Hertfordshire) and informed consent. All other methods are described in [*SI Appendix*, *SI Materials and Methods*](http://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1811866115/-/DCSupplemental).

Data Availability. {#s11}
------------------

The RNA-seq data have been deposited in the European Nucleotide Archive (accession no. ERP024278).
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